Yeardisk Creator Suite 6.01 Crack Patch

1. American Academy of Ophthalmology. Dry Eye syndrome-Preferred practice patterns. American Academy of Ophthalmology; 2003.

2. Market ScopeReport on the global dry eye market. St. Louis, MO: 2004.

3. Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003;136:318–326. [PubMed]

4. Lemp MA. Report of the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eyes. CLAO J. 1995;21:221–232. [PubMed]

5. Lemp MA, Baudouin C, Baum J, et al. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Work Shop (2007) Ocular Surf. 2007;5:75–92. [PubMed]

6. Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC. The Pathology of Dry Eye: The Interaction Between the Ocular Surface and Lacrimal Glands. Cornea. 1998;17:584–589. [PubMed]

7. Stern ME, Gao J, Siemasko KF, et al. The role of the lacrimal functional unit in the Pathophysiology of dry eye. Exp Eye Res. 2004;78:409–416. [PubMed]

8. Report of the Epidemiology Subcommittee of the International Dry Eye Work Shop: The epidemiology of dry eye disease. Ocul Surf. 2007;5:93–107. [PubMed]

9. De Paiva CS, Corrales RM, Villarreal AL, et al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAP K activation in the corneal epithelium in experimental dry eye. Exp Eye Res. 2006;83:526–535. [PubMed]

10. Management and Therapy Subcommittee. Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye Work-Shop (2007) Ocul Surf. 2007;5:163–178. [PubMed]

11. Luo L, Li DQ, Doshi A, et al. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAP K signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci. 2004;45:4293–4301. [PubMed]

12. Stern ME, Pflugfelder SC. Inflammation in dry eye. Ocular Surf. 2004;2:124–130. [PubMed]

13. Roberts CW, Carniglia PE, Brazzo BG. Comparison of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eye. Cornea. 2007;26:805–809. [PubMed]

14. Meadows M. Dealing with Dry Eye. FDA Consumer Magazine; 2005. [PubMed]

15. Dupont AC, Bagg SD, Baker L, Creasy JL, Romano C, Romano D, Richmond FJR, Loeb GE. First patients with BION implants for therapeutic electrical stimulation. Neuromodulation. 2004;7:38–47. [PubMed]

16. Loeb GE, Richmond FJR, Singh J, Peck RA, Tan W, Zou Q, Sachs N. RF-Powered BIONs for Stimulation and Sensing, Proc. 26th Ann. Intl. Conference IEEE Engineering in Medicine and Biology Society; San Francisco. Sept. 1–5; 2004. [PubMed]

17. Baker L, Waters R, Winstein C, Kaplan H, Tran W, Richmond FJR, Loeb GE. Clinical Applications of BION(TM) Microstimulators. First International Conf. on Neural Interface and Control; Wuhan, China. May 26–28, 2005; 2005.

18. Dupont AC, Bagg SD, Chun S, Creasy JL, Romano C, Romano D, Waters RL, Wederich CL, Richmond FJR, Loeb GE. IFESS. LJUBLJANA; SLOVENIA: 2002. Clinical Trials of BION™ Microstimulators.

19. Schwedt TJ, Dodick DW, Hentz J, et al. Occipital nerve stimulation for chronic headache: long-term safety and efficacy. Cephalalgia. 2007;27:153–157. [PubMed]

20. Saper JR, Dodick DW, Silberstein SD, et al. Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia. 2011;31:271–285. [PMC free article] [PubMed]

21. Tubaro A. Sacral root neuromodulation in the treatment of refractory urinary urge incontinence: a prospective randomized clinical trial. Current Opinion in Urology. 2000;10:489–490.

22. Tjandra JJ, Lim JF, Matzel K. Sacral nerve stimulation: An emerging treatment for fecal incontinence. ANZ Journal of Surgery. 2004;74:1098–1106. [PubMed]

23. Wang J, Aquavella JV, Palakuru JR, Chung S, Feng C. Relationships between central tear film thickness and tear menisci of the upper and lower eyelids. Investigative Ophthalmology & Visual Science. 2006;47:4349–4355. [PubMed]

24. Palakuru JR, Wang J, Aquavella JV. Effect of blinking on tear dynamics. Investigative Ophthalmology & Visual Science. 2007;48:3032–3037. [PubMed]

25. Wang J, Aquavella JV, Palakuru JR, Chung S. Repeated measurements of dynamic tear distribution on the ocular surface after instillation of artificial tears. Investigative Ophthalmology & Visual Science. 2006;47:3325–3329. [PMC free article] [PubMed]

26. Shen M, Li J, Wang J, et al. Upper and lower tear menisci in the diagnosis of dry eye. Invest Ophthalmol Vis Sci. 2009;50:2722–2726. [PubMed]

27. Wang J, Abou Shousha M, Perez VL, Karp CL, Yoo SH, Shen M, Cui L, Humeric V, Du C, Zhu D, Chen Q, Li M. Ultra-high resolution optical coherence tomography for imaging the anterior segment of the eye. Ophthalmic Surg Lasers Imaging. 2011;42:S15–27. [PubMed]

28. Li M, Du C, Zhu D, Shen M, Cui L, Wang J. Daytime variations of tear osmolarity and tear meniscus volume. Eye Contact Lens. 2012;38:282–287. [PMC free article] [PubMed]


30. Barabino S, Dana MR. Animal models of dry eye: a critical assessment of opportunities and limitations. Invest Ophthalmol Vis Sci. 2004;45:1641–1646. [PubMed]

31. Barabino S, Chen W, Dana MR. Tear film and ocular surface tests in animal models of dry eye: uses and limitations. Experimental Eye Research. 2004;79:613–621. [PubMed]

32. Scifo C, Barabino S, De Pasquale G, Blanco AR, Mazzone MG, Rolando M. Effects of a New Lipid Tear Substitute in a Mouse Model of Dry Eye. Cornea. 2010;29:802–806. [PubMed]

33. Nakamura S, Okada S, Umeda Y, Saito F. Development of a Rabbit Model of Tear Film Instability and Evaluation of Viscocity of Artificial Tear Preparations. Cornea. 2004;23:390–397. [PubMed]

34. Gao J, Schwalb TA, Adeeo JV, Ghosn CR, Stern ME. The Role of Apoptosis in the Pathogenesis of Canine Keratoconjunctivitis Sicca: The Effect of Topical Cyclosporin A Therapy. Cornea. 1998;17:654. [PubMed]

35. Botelho S, Mituhiko H, Fuenmayor N. Functional Innervation of the Lacrimal Gland in the Cat. Origin of the Secretomotor Fibers in the Lacrimal Nerve. Arch Ophthal Vol. 1966;76:581–589. [PubMed]

36. Lundberg A. The Electrophysiology of the Submaxillary Gland of the Cat. Acta Physiol Scand. 1955;35:1–25. [PubMed]

37. Lundberg A. Secretory Potentials in the Sublingual Gland of the Cat. Acta Physiol Scand. 1957;40:21–34. [PubMed]

38. Arenson MS, Wilson H. The parasympathetic secretory nerves of the lacrimal gland of the cat. Journal of Physiology. 1971;217:201–212. [PMC free article] [PubMed]

39. Wikberg JE. Synthesis of 3H-acetylcholine in the rabbit lacrimal gland and its release by electrical field stimulation. Acta Physiologica Scandinavica. 1979;105:108–113. [PubMed]

40. Arenson MS, Wilson H. The peripheral parasympathetic innervation of the cat lacrimal gland. British Journal of Pharmacology. 1970;39:242–243. [PMC free article] [PubMed]

41. Yoo PB, Woock JP, Grill WM. Bladder activation by selective stimulation of pudendal nerve afferents in the cat. Experimental Neurology. 2008;212:218–255. [PMC free article] [PubMed]

42. Van Kerrebroek P, Van Voskusilen A, Heesakkers J, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of prospective, worldwide clinical study. J Urol. 2007;178:2029–2034. [PubMed]

43. Nguyen P, Hugang D, Li Y, Sadda SR, Ramos S, Pappuru RR, Yiu SC. Correlation Between Optical Coherence Tomography-Derived Assessments of Lower Tear Meniscus Parameters and Clinical Features of Dry Eye Disease. Cornea. 2012;31:680–685. [PMC free article] [PubMed]

44. Nichols KK, Mitchell GL, Zadnik K. The repeatability of clinical measurements of dry eye. Cornea. 2004;23:272–285. [PubMed]

45. Nichols KK, Nichols JJ, Mitchell GL. The lack of association between signs and symptoms in patients with dry eye disease. Cornea. 2004;23:762–770. [PubMed]

46. Schein OD, Tielsch JM, Munõz B, et al. Relation between signs and symptoms of dry eye in the elderly. A population-based perspective. Ophthalmology. 1997;104:1395–1401. [PubMed]

47. Park D, Lew H, Lee SY. Tear meniscus measurement in nasolacrimal duct obstruction patient with Fourier-domain optical coherence tomography: novel three-point capture method. Acta Ophthalmologica. 2012;90:783–787. [PubMed]

48. Qiu X, Gong L, Lu Y, Jin H, Robitaille M. The diagnostic significance of Fourier-domain optical coherence tomography in Sjogren syndrome, aqueous tear deficiency and lipid tear deficiency patients. Acta Ophthalmologica. 2012;90:e359–366. [PubMed]

49. Cui L, Wang J, Perez VL, Shen M, Yuan Y, Wang M. Visualization of the Precorneal Tear Film Using Ultrahigh Resolution Optical Coherence Tomography in Dry Eye. Eye & Contact Lens: Science & Clinical Practice. 2012;38:240–244. [PMC free article] [PubMed]

50. Huang D, Swanson EA, Lin CP, et al. Optical coherence tomography. Science. 1991;254:1178–1181. [PMC free article] [PubMed]

51. Huang D, Izatt JA, Yasuno Y, et al. Future direction of anterior segment optical coherence tomography. In: Steinert RF, Huang D, editors. Anterior Segment Optical Coherence Tomography Thorofare. NJ: SLACK Inc; 2008. pp. 165–173.

52. Zhou S, Li Y, Lu AT, et al. Reproducibility of tear meniscus measurement by Fourier-domain optical coherence tomography: a pilot study. Ophthalmic Surg Lasers Imaging. 2009;40:442–447. [PMC free article] [PubMed]

53. Bitton E, Keech A, Simpson T, et al. Variability of the analysis of the tear meniscus height by optical coherence tomography. Optom Vis Sci. 2007;84:903–908. [PubMed]

54. Ibrahim OM, Dogru M, Takano Y, et al. Application of visante optical coherence tomography tear meniscus height measurement in the diagnosis of dry eye disease. Ophthalmology. 2010;117:1923–1929. [PubMed]

55. Johnson ME, Murphy PJ. The agreement and repeatability of tear meniscus height measurement methods. Optom Vis Sci. 2005;82:1030–1037. [PubMed]

56. Savini G, Barboni P, Zanini M. Tear meniscus evaluation by optical coherence tomography. Ophthalmic Surg Lasers Imaging. 2006;37:112–118. [PubMed]